Clinical trials: Residual Disease
Hemorrhagic Shock, Pediatric Trauma
Effect of Resuscitation on Gastric Emptying Using POCUS in Pediatric Trauma Patients
Pediatric trauma often leads to hemorrhagic shock, which reduces blood flow to the digestive tract and delays gastric emptying. This delay can cause fluid and food to remain in the stomach, increasing the risk of pulmonary…
- Conditions
- Hemorrhagic Shock, Pediatric Trauma, Delayed Gastric Emptying, Gastric Dysmotility
- Trial name
- NCT07810907
- Volunteers
- 50 people
- Sponsor
- Assiut University
Minimal Residual Disease, Fertility Preservation
Contamination of Testicle Tissue by RT-PCR in Participants With Solid Tumors
For prepubertal patients, cryopreservation of testicular tissue is the only option available to preserve their fertility before cancer treatment.
- Trial name
- TESTIMAR (NCT02400970)
- Testing
- malignant cells
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Clermont-Ferrand
Diabetic Macular Edema
Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab
This is an open-label, Phase I/II study of intravitreally administered ranibizumab either 0.5-mg and/or 2.0-mg in subjects with clinical, angiographic, and ocular coherence tomography (OCT) evidence of diabetic retinopathy with…
- Trial name
- REEF (NCT01292798)
- Testing
- Ranibizumab
- Where
- 5 sites in United States
- Volunteers
- 43 people
- Sponsor
- California Retina Consultants
Gastric Residual Volume, Abdominal Distension
Abdominal Massage for Gastric Residual Volume in Surgical Patients
This randomized controlled trial aimed to evaluate the effect of abdominal massage on gastric residual volume (GRV) and abdominal distension in surgical intensive care patients receiving enteral nutrition.
- Conditions
- Gastric Residual Volume, Abdominal Distension, Enteral Nutrition, Massage Therapy
- Trial name
- NCT07018414
- Testing
- Abdominal Massage
- Where
- Turkey (Türkiye)
- Volunteers
- 84 people
- Sponsor
- Marmara University
Acute Myeloid Leukemia
MRD Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia
This is a non-therapeutic study. Pediatric AML patients undergoing HCT with a myeloablative preparative regimen may be enrolled. Subjects can be enrolled 10-40 days prior to HCT.
- Trial name
- NCT01385787
- Where
- 38 sites in United States, Canada
- Volunteers
- 150 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Cancer
Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL
SNX-5422 is a prodrug of SNX-2112, a potent, highly selective, small molecule inhibitor of the molecular chaperone heat shock protein 90 (HSP90).
- Trial name
- NCT02973399
- Testing
- SNX-5422 plus ibrutinib
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Esanex Inc.
Rectal Adenocarcinoma, Circulating Tumor DNA
Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology
The purpose of this study is to study the performance of MRD monitoring in predicting the efficacy and prognosis of neoadjuvant therapy in patients with rectal cancer, and to explore the value of MRD detection in evaluating the…
- Conditions
- Rectal Adenocarcinoma, Circulating Tumor DNA, Minimal Residual Disease, Neoadjuvant Chemoradiotherapy
- Trial name
- NCT05969938
- Testing
- MRD detection
- Where
- China
- Volunteers
- 50 people
- Sponsor
- WeiWei Xiao
TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease
CtDNA Based MRD Testing for NAC Monitoring in TNBC
A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR) after neoadjuvant…
- Trial name
- B-STRONGER-I (NCT06230185)
- Where
- 14 sites in United States
- Volunteers
- 422 people
- Sponsor
- Personalis Inc.
Acute Myeloid Leukemia
Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.
The primary purpose of this study was to test the hypothesis that preemptive treatment with sabatolimab, alone or in combination with azacitidine, when administered to participants with Acute myeloid leukemia (AML)/secondary AML…
- Trial name
- NCT04623216
- Testing
- Sabatolimab, Azacitidine
- Where
- 9 sites in France, Germany and 2 more
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Lung Neoplasms, Neoadjuvant Therapy
MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer
This study is a prospective single-arm clinical trial targeting patients with stage IB-IIIA non-small cell lung cancer (NSCLC) who have received neoadjuvant immunotherapy.
- Conditions
- Lung Neoplasms, Neoadjuvant Therapy, Immunotherapy, Minimal Residual Disease
- Trial name
- NCT07894458
- Testing
- Adaptive therapy of de-escalation and escalation based on MRD testing and pathological response
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Patent Foramen Ovale, Closure; Foramen Ovale
Residual Shunt After Patent Foramen Ovale Device Closure in Patients With Cryptogenic Stroke
Among consecutive 47 cryptogenic stroke patients who underwent PFO closure, a serial follow-up bubble contrast TEE at 3 and 9 months after the index procedure was completed in 38 patients (81%, 46±10 years, 19 men).
- Trial name
- NCT03416426
- Testing
- Amplatzer® PFO occluder or Gore® Septal Occluder
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Gachon University Gil Medical Center
CML (Chronic Myelogenous Leukemia
IIT PH1 KDS-1001 in Patients With CML
This open label, non-randomized, prospective phase I study is designed to evaluate if the addition of natural killer cell therapy (KDS-1001) to tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) patients with…
- Trial name
- NCT04808115
- Testing
- KDS-1001
- Sponsor
- Duke University
Locally Advanced Head and Neck Carcinoma
cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas
The goal of this ancillary clinical trial is to evaluated circulating DNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carninoma.
- Trial name
- NeckTAR-IN (NCT07178847)
- Testing
- blood sampling
- Where
- 4 sites in France
- Volunteers
- 59 people
- Sponsor
- Centre Jean Perrin
Leukemia, Lymphocytic, Chronic, B-Cell
Phase II Trial GA101 Inbrutinib B CLL
Phase II study testing chemo-free induction therapy with Ibrutinib + Obinutuzumab nine months / Study Part 1: All patients will receive 8 courses of GA101 + ibrutinib 420mg PO every 28 days Study Part 2: After evaluation at D1 of…
- Trial name
- ICLL07GAI (NCT02666898)
- Testing
- GA101, Ibrutinib, Cyclophosphamide
- Where
- France
- Volunteers
- 135 people
- Sponsor
- French Innovative Leukemia Organisation
Speech Sound Disorder
Beatboxing and Residual Speech Errors
This project will study the effect of practicing speech sounds via beatboxing on speech accuracy, engagement in therapy, and functional outcomes for older children and adolescents with speech sound disorders (SSDs).
- Trial name
- NCT03972449
- Testing
- BEAT-Speech, Traditional Articulation Approach
- Volunteers
- healthy volunteers welcome
- Sponsor
- Duquesne University
Ovarian Cancer
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug with peripheral stem cell transplantation may allow the doctor to give higher…
- Trial name
- NCT00003413
- Testing
- filgrastim, carmustine, cisplatin
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Maryland, Baltimore
CLL, SLL
A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
The purpose of this study is to find out whether people with CLL or SLL who are currently receiving treatment with ibrutinib can stop treatment and remain off-treatment for at least 12 months, if they have achieved complete or…
- Conditions
- CLL, SLL, CLL/SLL, Chronic Lymphocytic Leukemia
- Trial name
- NCT04694560
- Testing
- Treatment Free Observation
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Osteoarthritis, Hip, Femoroacetabular Impingement
Early Feasibility Study of Cartilage Defect Repair
Any patient aged 14 or older up to 64 years of age with hip disease, resulting in loss of articular cartilage integrity on the femoral head (e.g., femoroacetabular impingement or other structural deformity), has failed…
- Conditions
- Osteoarthritis, Hip, Femoroacetabular Impingement, Osteonecrosis, Legg-Calvé-Perthes Disease
- Trial name
- NCT06823089
- Testing
- ReNew Hip Implant
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Cytex Therapeutics, Inc.
Hyperhidrosis, Residual Limbs
Topical Aluminium Chloride vs OnabotulinumtoxinA Intradermal Injections in Residual Limb Hyperhidrosis (Lower Limbs)
The aim of this study is to demonstrate onabotulinumtoxinA superiority to aluminium chloride for the treatment of residual limb hyperhidrosis.
- Trial name
- SALUTOX (NCT03433859)
- Testing
- OnabotulinumtoxinA, Topical Aluminium Chloride (cosmetic product)
- Where
- 9 sites in France
- Volunteers
- 54 people
- Sponsor
- Direction Centrale du Service de Santé des Armées
Prostate Cancer
Imaging of Residual Tumor During Prostatectomy
Prostate Cancer is the most common cancer in men, affecting about as many men as women diagnosed with breast cancer, and killing about as many men per year as breast cancer kills women.
- Trial name
- NCT01173146
- Where
- United States
- Sponsor
- Spectros Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.